Cargando…

Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy

BACKGROUND: Despite the advent of checkpoint inhibitors (CPIs) for advanced genitourinary (GU) cancers, existing studies suggest that durable complete responses are observed in fewer than 10% of patients. This study sought to evaluate the association between expectations of cure reported by patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergerot, Cristiane Decat, Bergerot, Paulo Gustavo, Philip, Errol J., Hsu, Jo Ann, Dizman, Nazli, Vaishampayan, Ulka, Dorff, Tanya, Pal, Sumanta Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416952/
https://www.ncbi.nlm.nih.gov/pubmed/30867071
http://dx.doi.org/10.1186/s40425-019-0557-5
_version_ 1783403463392100352
author Bergerot, Cristiane Decat
Bergerot, Paulo Gustavo
Philip, Errol J.
Hsu, Jo Ann
Dizman, Nazli
Vaishampayan, Ulka
Dorff, Tanya
Pal, Sumanta Kumar
author_facet Bergerot, Cristiane Decat
Bergerot, Paulo Gustavo
Philip, Errol J.
Hsu, Jo Ann
Dizman, Nazli
Vaishampayan, Ulka
Dorff, Tanya
Pal, Sumanta Kumar
author_sort Bergerot, Cristiane Decat
collection PubMed
description BACKGROUND: Despite the advent of checkpoint inhibitors (CPIs) for advanced genitourinary (GU) cancers, existing studies suggest that durable complete responses are observed in fewer than 10% of patients. This study sought to evaluate the association between expectations of cure reported by patients with advanced GU cancers initiating immunotherapy and quality of life (QOL), anxiety and depression. PATIENT AND METHODS: A single-institution, cross-sectional survey study was conducted with patients preparing to receive CPIs for treatment of metastatic renal cell carcinoma (RCC), urothelial cancer (UC) and prostate cancer (PC). Patients were assessed prior to initiation of immunotherapy for expectations of cure (divided into four quartiles), quality of life (QOL; Functional Assessment of Chronic Illness Therapy-General [FACT-G]), and symptoms of anxiety and depression (PROMIS). RESULTS: Sixty patients were enrolled, with metastatic RCC, UC and PC comprising 63, 28 and 8% of the study population, respectively. Median age of the cohort was 65 (range, 31–91), and 68% were male; 33% received CPI in the first-line setting. Despite extensive counseling from oncologists regarding potential clinical outcomes with immunotherapy, a substantial proportion of patients (23%) harbored inaccurate expectations regarding the potential benefit of immunotherapy. Importantly, patients with accurate expectations of cure reported lower anxiety scores using the PROMIS-Anxiety inventory. No significant differences were found between expectations of cure and quality of life or depression, using the FACT-G and PROMIS-Depression inventories, respectively. CONCLUSION: The current study found that a considerable proportion of patients with advanced GU cancers harbor inaccurate expectations concerning the potential benefit of immunotherapy. These results suggest that more effective counselling may mitigate patient anxiety, and potentially promote treatment satisfaction and adherence.
format Online
Article
Text
id pubmed-6416952
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64169522019-03-25 Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy Bergerot, Cristiane Decat Bergerot, Paulo Gustavo Philip, Errol J. Hsu, Jo Ann Dizman, Nazli Vaishampayan, Ulka Dorff, Tanya Pal, Sumanta Kumar J Immunother Cancer Short Report BACKGROUND: Despite the advent of checkpoint inhibitors (CPIs) for advanced genitourinary (GU) cancers, existing studies suggest that durable complete responses are observed in fewer than 10% of patients. This study sought to evaluate the association between expectations of cure reported by patients with advanced GU cancers initiating immunotherapy and quality of life (QOL), anxiety and depression. PATIENT AND METHODS: A single-institution, cross-sectional survey study was conducted with patients preparing to receive CPIs for treatment of metastatic renal cell carcinoma (RCC), urothelial cancer (UC) and prostate cancer (PC). Patients were assessed prior to initiation of immunotherapy for expectations of cure (divided into four quartiles), quality of life (QOL; Functional Assessment of Chronic Illness Therapy-General [FACT-G]), and symptoms of anxiety and depression (PROMIS). RESULTS: Sixty patients were enrolled, with metastatic RCC, UC and PC comprising 63, 28 and 8% of the study population, respectively. Median age of the cohort was 65 (range, 31–91), and 68% were male; 33% received CPI in the first-line setting. Despite extensive counseling from oncologists regarding potential clinical outcomes with immunotherapy, a substantial proportion of patients (23%) harbored inaccurate expectations regarding the potential benefit of immunotherapy. Importantly, patients with accurate expectations of cure reported lower anxiety scores using the PROMIS-Anxiety inventory. No significant differences were found between expectations of cure and quality of life or depression, using the FACT-G and PROMIS-Depression inventories, respectively. CONCLUSION: The current study found that a considerable proportion of patients with advanced GU cancers harbor inaccurate expectations concerning the potential benefit of immunotherapy. These results suggest that more effective counselling may mitigate patient anxiety, and potentially promote treatment satisfaction and adherence. BioMed Central 2019-03-12 /pmc/articles/PMC6416952/ /pubmed/30867071 http://dx.doi.org/10.1186/s40425-019-0557-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Short Report
Bergerot, Cristiane Decat
Bergerot, Paulo Gustavo
Philip, Errol J.
Hsu, Jo Ann
Dizman, Nazli
Vaishampayan, Ulka
Dorff, Tanya
Pal, Sumanta Kumar
Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
title Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
title_full Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
title_fullStr Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
title_full_unstemmed Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
title_short Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
title_sort perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416952/
https://www.ncbi.nlm.nih.gov/pubmed/30867071
http://dx.doi.org/10.1186/s40425-019-0557-5
work_keys_str_mv AT bergerotcristianedecat perceptionofcureamongpatientswithmetastaticgenitourinarycancerinitiatingimmunotherapy
AT bergerotpaulogustavo perceptionofcureamongpatientswithmetastaticgenitourinarycancerinitiatingimmunotherapy
AT philiperrolj perceptionofcureamongpatientswithmetastaticgenitourinarycancerinitiatingimmunotherapy
AT hsujoann perceptionofcureamongpatientswithmetastaticgenitourinarycancerinitiatingimmunotherapy
AT dizmannazli perceptionofcureamongpatientswithmetastaticgenitourinarycancerinitiatingimmunotherapy
AT vaishampayanulka perceptionofcureamongpatientswithmetastaticgenitourinarycancerinitiatingimmunotherapy
AT dorfftanya perceptionofcureamongpatientswithmetastaticgenitourinarycancerinitiatingimmunotherapy
AT palsumantakumar perceptionofcureamongpatientswithmetastaticgenitourinarycancerinitiatingimmunotherapy